The study evaluates the safety of eptifibatide in the treatment of acute respiratory distress syndrome (ARDS), which has a high mortality rate and where antiplatelet therapy is important. Eptifibatide is a glycoprotein receptor IIb/IIIa inhibitor, used mainly in acute coronary syndromes, non-venous thromboembolic pulmonary embolism, ARDS and septic shock. Adverse event reports from the FAERS database since 2004, where eptifibatide was the primary suspect drug, were analyzed. Methods such as Bayesian Neupagation Healthcare Network, PNN Healthcare Profidence, MHRA, MGPS, PRR and ROR were used. New adverse reactions were identified, including acute myocardial infarction, cardiac arrest, nausea, hemorrhagic pancreatitis, tremors, dyspnoea, and vascular pseudoaneurysm. The study highlights the importance of early detection of these reactions. The results provide an overview of the known and new risks of eptifibatide in real-world clinical use in ARDS for better prescribing by physicians.